trial

Enhancing Motivation in Recent Onset Schizophrenia

NCTId NCT01817387
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 20 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2018-03-20
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
20 (actual)
Study type
Interventional
Allocation
Randomized
Model
Factorial
Masking
Single
Start
2014-07
Primary completion
2018-03-20
Eligibility
ALL · 14 Years · 30 Years

Interventions & indications

Drugs
PRIMECognitive training

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor

Investigators

1
Danielle A Schlosser, PhDPrincipal Investigator

Sites

1 total
San Francisco, United States

Facts & assertions

4 sourced
Enrollment
20
Phase
NA
Primary Completion Date
2018-03-20
Status
TERMINATED
relationships
The graph out of here
drug
PRIME
drug
Cognitive training
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Danielle A Schlosser, PhD
person